Identification of novel diagnostic biomarkers for thyroid carcinoma

N/ACitations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Thyroid carcinoma (THCA) is the most universal endocrine malignancy worldwide. Unfortunately, a limited number of large-scale analyses have been performed to identify biomarkers for THCA. Here, we conducted a meta-analysis using 505 THCA patients and 59 normal controls from The Cancer Genome Atlas. After identifying differentially expressed long non-coding RNA (lncRNA) and protein coding genes (PCG), we found vast difference in various lncRNA-PCG co-expressed pairs in THCA. A dysregulation network with scale-free topology was constructed. Four molecules (LA16c-380H5.2, RP11-203J24.8, MLF1 and SDC4) could potentially serve as diagnostic biomarkers of THCA with high sensitivity and specificity. We further represent a diagnostic panel with expression cutoff values. Our results demonstrate the potential application of those four molecules as novel independent biomarkers for THCA diagnosis.

Cite

CITATION STYLE

APA

Wang, X., Zhang, Q., Cai, Z., Dai, Y., & Mou, L. (2017). Identification of novel diagnostic biomarkers for thyroid carcinoma. Oncotarget, 8(67), 111551–111566. https://doi.org/10.18632/oncotarget.22873

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free